Compare Cintas Corporation (CTAS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Eli Lilly And Co — how do they compare? Cintas Corporation trades at $200.75 (market cap $78.78B), while Eli Lilly And Co trades at $1,167.38 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 13.5× Cintas Corporation's market cap, and Cintas Corporation pays the higher dividend (1.05%). Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Eli Lilly And Co for 93 Days on average.
| CTAS | LLY | |
|---|---|---|
Market Cap | $78.78B | $1.06T |
Volume | 1,620,783 | 2,297,239 |
Sector | Industrials | Health |
52-Week High | $216.53 | $1.28K |
52-Week Low | $163.55 | $799.57 |
Typical Hold Time | 124 Days | 93 Days |
Enterprise Value | $81.25B | $1.11T |
Dividend Yield | 1.05% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal and strong fundamental performance. Recent Q1 2027 earnings beat expectations with revenue of $3.01 billion and EPS of $1.39, driven by organic growth and margin expansion. The company raised fiscal 2027 guidance, reflecting confidence in continued momentum. Valuation multiples remain elevated with a P/E of 38.89, supported by robust profitability metrics including a 17.82% net income margin and 42.08% ROE.
The outlook for CTAS is positive, with earnings growth and raised guidance serving as key catalysts for potential upside toward the consensus price target of $234.60. Risks include high valuation sensitivity to growth sustainability and competitive pressures in the uniform rental sector. Analyst sentiment is moderately bullish, with 40% buy ratings, but investors should monitor execution against elevated expectations.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
